Wnt信号通过胶质瘤内皮细胞转胞吞调控MFSD2A依赖的药物递送
研究在CT2A和PDGFB驱动的RCAS/tv-a原位胶质瘤模型中,发现抑制Wnt信号(LGK974)可增加替莫唑胺递送并增敏化疗;转录组分析显示Wnt抑制上调PLVAP、下调MFSD2A,增强血管转胞吞;Mfsd2a缺陷增强替莫唑胺递送,而内皮细胞组成性表达Mfsd2a则抑制Wnt抑制诱导的递送增强;Wnt抑制还增强Cav1阳性小窝介导的转胞吞,且Wnt抑制剂或Mfsd2a缺陷在Cav1缺陷小鼠中不能增强替莫唑胺渗透。结论:Wnt信号通过小窝介导的内皮细胞转胞吞通路调控MFSD2A依赖的替莫唑胺递送,Wnt信号是改善胶质母细胞瘤药物递送的潜在治疗靶点。
要点
- LGK974抑制Wnt信号可增加两种小鼠胶质瘤模型中的替莫唑胺递送并增敏化疗。
- Wnt抑制上调PLVAP、下调MFSD2A,增强血管转胞吞。
- Mfsd2a缺陷增强肿瘤内替莫唑胺递送,内皮细胞组成性表达Mfsd2a则抑制Wnt抑制诱导的递送增强。
核心结论
- Wnt信号通过小窝介导的内皮细胞转胞吞通路调控MFSD2A依赖的替莫唑胺递送。
- Wnt信号是改善胶质母细胞瘤治疗药物递送的潜在治疗靶点。
研究设计与样本
- 在CT2A和PDGFB驱动的RCAS/tv-a原位胶质瘤模型中研究替莫唑胺递送。
- 对小鼠胶质瘤内皮细胞进行转录组分析。
- 构建Mfsd2a缺陷、Cav1缺陷和Mfsd2a内皮细胞特异性诱导小鼠研究分子机制。
主要发现
- LGK974抑制Wnt信号可增加替莫唑胺递送并增敏化疗。
- Wnt抑制上调PLVAP、下调MFSD2A,增强血管转胞吞。
- Mfsd2a缺陷增强肿瘤内替莫唑胺递送,内皮细胞组成性表达Mfsd2a抑制Wnt抑制诱导的递送增强。
- Wnt抑制增强Cav1阳性小窝介导的转胞吞。
- Wnt抑制剂或Mfsd2a缺陷在Cav1缺陷小鼠中不能增强替莫唑胺渗透。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic delivery of anti-tumor therapeutic agents to brain tumors is thwarted by the blood-brain barrier (BBB), an organotypic specialization of brain endothelial cells (ECs). A failure of pharmacological compounds to cross BBB is one culprit for the dismal prognosis of glioblastoma (GBM) patients. Identification of novel vascular targets to overcome the challenges posed by the BBB in tumors for GBM treatment is urgently needed. METHODS: Temozolomide (TMZ) delivery was investigated in CT2A and PDGFB-driven RCAS/tv-a orthotopic glioma models. Transcriptome analysis was performed on ECs from murine gliomas. Mfsd2a deficient, Cav1 deficient, and Mfsd2a EC-specific inducible mice were developed to study the underlying molecular mechanisms. RESULTS: We demonstrated that inhibiting Wnt signaling by LGK974 could increase TMZ delivery and sensitize glioma to chemotherapy in both murine glioma models. Transcriptome analysis of ECs from murine gliomas revealed that Wnt signaling inhibition enhanced vascular transcytosis as indicated by the upregulation of PLVAP and downregulation of MFSD2A. Mfsd2a deficiency in mice enhances TMZ delivery in tumors, whereas constitutive expression of Mfsd2a in ECs suppresses the enhanced TMZ delivery induced by Wnt pathway inhibition in murine glioma. In addition, Wnt signaling inhibition enhanced caveolin-1 (Cav1)-positive caveolae-mediated transcytosis in tumor ECs. Moreover, Wnt signaling inhibitor or Mfsd2a deficiency fails to enhance TMZ penetration in tumors from Cav1-deficient mice. CONCLUSIONS: These results demonstrated that Wnt signaling regulates MFSD2A-dependent TMZ delivery through a caveolae-mediated EC transcytosis pathway. Our findings identify Wnt signaling as a promising therapeutic target to improve drug delivery for GBM treatment.
引用
- Xie Y, He L, Zhang Y, et al. Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma. Neuro Oncol. 2023. PMID: 36591963. doi:10.1093/neuonc/noac288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。